ABSTRACT: To justify use in routine coronary heart disease (CHD) risk assessment, a novel serum biomarker must be specifically associated with future CHD events and add information beyond techniques currently available. Current risk assessment techniques are probabilistic and imperfect; however, to date, no novel serum biomarker has improved substantially on the current population-based risk stratification approach. Although limited trial-based data are available to assess the utility of biomarkers, insights gained from biomarkers may enhance clinical decision making. Continued basic science and population-based research into CHD biomarkers may help to further the capacity for CHD risk assessment.
The Medical clinics of North America 01/2012; 96(1):1-11. · 2.18 Impact Factor
ABSTRACT: The following Point/Counterpoint articles were derived from a debate presentation sponsored by the American Society for Preventive Cardiology at the March 2010 meeting of the American Heart Association Council on Epidemiology and Prevention, titled "Should We Focus on Novel Risk Marker and Screening Tests to Better Predict and Prevent Cardiovascular Disease?" Dr. James de Lemos presented the pro side, titled "Novel Risk Markers and Screening Tests Will Improve the Prediction and PRevention of Cardiovascular Disease," and Dr. Donald Lloyd-Jones advocated the con side, titled "Better Implementation of Existing Knowledge Will Save More Lives Than All of the Novel Biomarkers in the World." The following articles include points from the debate, rebuttal, and questions raised by the audience. We thank all authors for sharing this debate with the readership.
Preventive Cardiology 01/2010; 13(4):160-5.
ABSTRACT: Atherosclerotic disease develops over decades, thus preceding end-organ events, myocardial infarction, and stroke by many
years. Identifying risk factors for atherosclerotic disease development is necessary to guide early primary prevention measures.
The most widely accepted risk estimation tools, 10-year risk profiles, may not adequately predict true future burden of cardiovascular
disease. Lifetime risk assessment estimates the chance of developing a given disease before death and may be an important
adjunct to short-term risk estimation. Therefore, recent efforts to estimate lifetime risk have been developed to better characterize
the long-term burden of cardiovascular disease, compare absolute risks between common diseases, and guide preventive treatment
decisions for younger patients with cardiovascular risk factors. In this article, we discuss techniques of short-term (10-year)
and lifetime risk calculation and the benefits, limitations, and clinical implications of both techniques of risk assessment.
Current Cardiovascular Risk Reports 02/2009; 3(2):144-149.